Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | ABL1 | P00519 | 7/20 | 0.46 |
| ▸ | ABL2 | P42684 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGR | P09769 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5456749 | 0.99 | SRC (0.52) | SRCKDRABL1ABL2EGFR | |
| SCHEMBL5463324 | 0.88 | SRC (0.51) | SRCKDRABL1ABL2EGFR | |
| Hydrochloric Acid SCHEMBL5461965 | 0.88 | SRC (0.51) | SRCKDRABL1ABL2EGFR | |
| SCHEMBL3673893 | 0.85 | SRC (0.72) | SRCKDRABL1ABL2EGFR | |
| Hydrochloric Acid SCHEMBL7134322 | 0.84 | SRC (0.71) | SRCKDRABL1ABL2EGFR | |
| SCHEMBL5461942 | 0.82 | SRC (0.49) | SRCKDRABL1ABL2EGFR | |
| Hydrochloric Acid SCHEMBL5463205 | 0.82 | SRC (0.49) | SRCKDRABL1ABL2EGFR | |
| SCHEMBL3673891 | 0.79 | SRC (0.54) | SRCKDRABL1ABL2EGFR | |
| SCHEMBL4030906 | 0.78 | SRC (0.57) | SRCKDRABL1ABL2EGFR | |
| Hydrochloric Acid SCHEMBL7066964 | 0.78 | SRC (0.70) | SRCKDRABL1ABL2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | claimed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | claimed |
| EP-1521751-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | Astrazeneca AB (SE) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005284-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | disclosed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1521751-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | Astrazeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005284-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | SRC 147/4885KDR 555/4885ABL1 63/4885 |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | SRC 49/4885KDR 454/4885ABL1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.